Adaptive Biotech director sells 124K shares
Adaptive Biotechnologies Corp (ADPT) director Peter M. Neupert reported an option exercise and significant share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp (ADPT) director Peter M. Neupert reported an option exercise and significant share sales. He exercised 15,000 stock options for Common Stock at an exercise price of $6.32 per share, fully exhausting that option grant. On the same date, he sold an aggregate 124,690 shares of Common Stock in open-market transactions at weighted average prices around $25.10–$25.27 per share, as detailed in price-range footnotes.
Insights
Analyzing...
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
5 txns
Insider
NEUPERT PETER M
Role
Director
Sold
124,690 shs ($3.14M)
Approx. gross sale proceeds
$3.14M
Approx. exercise cost
$95K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F4 | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,000 | $6.32 | $95K |
| Sale | Common Stock F1 | 15,000 | $25.23 | $378K |
| Sale | Common Stock F2 | 40,000 | $25.10 | $1.00M |
| Sale | Common Stock F3 | 69,690 | $25.16 | $1.75M |
Holdings After Transaction:
Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 130,625 shares (Direct)
Footnotes (4)
- F1. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.21 to $25.27, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.17, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.14 to $25.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The option was fully vested and exercisable and would have expired on October 18, 2026.
Key Figures
Options Exercised: 15,000 shares
Option Exercise Price: $6.32 per share
Shares Sold Block 1: 15,000 shares at $25.23 per share
+5 more
8 metrics
Options Exercised
15,000 shares
Stock Option (right to buy) for Common Stock exercised on 2026-08-17
Option Exercise Price
$6.32 per share
Conversion or exercise price for 15,000 Stock Options
Shares Sold Block 1
15,000 shares at $25.23 per share
Common Stock sale on 2026-08-17 with weighted average pricing footnote F1
Shares Sold Block 2
40,000 shares at $25.10 per share
Common Stock sale on 2026-08-17 with weighted average pricing footnote F2
Shares Sold Block 3
69,690 shares at $25.16 per share
Common Stock sale on 2026-08-17 with weighted average pricing footnote F3
Total Shares Sold
124,690 shares
Aggregate Common Stock sold across three sale transactions on 2026-08-17
Option Expiration Date
October 18, 2026
Footnote F4 states the option would have expired on this date
Net Buy/Sell Shares
-124,690 shares
Transaction summary netBuySellShares indicating overall net-sell activity
Key Terms
Stock Option (right to buy), weighted average price, derivative security, beneficial ownership
4 terms
Stock Option (right to buy) financial
"security_title is Stock Option (right to buy) for derivative transaction"
weighted average price financial
"The price reported for this transaction is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
beneficial ownership financial
"within the ranges set forth in any footnotes to this Form 4."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ADPT director Peter M. Neupert report in this Form 4?
Peter M. Neupert reported exercising 15,000 stock options and selling 124,690 shares of Adaptive Biotechnologies Corp Common Stock. The sales occurred in multiple open-market transactions at weighted average prices in the mid-$25 range.
How many Adaptive Biotechnologies (ADPT) options did Peter M. Neupert exercise?
He exercised 15,000 stock options for ADPT Common Stock at an exercise price of $6.32 per share. The option was fully vested, exercisable, and would have expired on October 18, 2026 before this exercise.
Did the exercised ADPT stock option remain outstanding after these transactions?
No. After exercising 15,000 options at $6.32 per share, the filing shows 0 derivative shares remaining from that specific option grant, indicating it was fully used and no longer outstanding.
AI-generated analysis. How Rhea-AI works. Not financial advice.
